USPSTF: Refer Children With High BMI to Behavioral Interventions
18 Jun 2024
TUESDAY, June 18, 2024 -- The U.S Preventive Services Task Force (USPSTF) recommends that clinicians refer children aged 6 years or older with a high body mass index (BMI) to comprehensive intensive behavioral interventions. These recommendations form the basis of a final recommendation statement published online June 18 in the Journal of the American Medical Association.
Elizabeth A. O'Connor, Ph.D., from the Kaiser Permanente Evidence-based Practice Center in Portland, Oregon, and colleagues examined the benefits and harms of weight management interventions initiated in health care settings among children aged 2 to 18 years with high BMI. Data were included from 58 randomized clinical trials with 10,143 participants. The researchers found that after six to 12 months, behavioral interventions were associated with small reductions in BMI and other weight outcomes. In interventions with higher contact hours and that offered physical activity sessions, larger effects were seen. For outcomes other than BMI, reporting was sparse, with few significant findings. The largest effect on BMI was seen for semaglutide and phentermine/topiramate. The few studies that assessed outcomes after discontinuation of medication showed immediate weight regain.
Based on these findings, the USPSTF concludes there is a moderate net benefit to providing or referring children and adolescents aged 6 years or older with a high BMI (≥95th percentile for age and sex) to comprehensive, intensive behavioral interventions (B recommendation).
"There are a variety of effective intensive behavioral interventions available that can help kids with a high BMI achieve a healthy weight, while improving quality of life," USPSTF member John M. Ruiz, Ph.D., said in a statement.
Evidence Report
Final Recommendation Statement
Editorial 1 (subscription or payment may be required)
Editorial 2 (subscription or payment may be required)
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.